MARTELLUCCI, IGNAZIO
MARTELLUCCI, IGNAZIO
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients
2006-01-01 Correale, P.; Cerretani, D.; Remondo, C.; Martellucci, I.; Marsili, S.; La Placa, M.; Sciandivasci, A.; Paolelli, L.; Pascucci, A.; Rossi, M.; Di Bisceglie, M.; Giorgi, G.; Gotti, G.; Francini, G.
Bevacizumab and weekly Doxetacel in patients with metastatic castrate-resistant prostate cancer previously exposed to Docetaxel
2011-01-01 Francini, F.; Pascucci, A.; Francini, E.; Bargagli, G.; Conca, R.; Licchetta, A.; Roviello, G.; Martellucci, I.; Chiriacò, G.; Miano, S:t.; Marzocca, G.; Manganelli, A.; Ponchietti, R.; Savelli, V.; Petrioli, R.
Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: A single-institution experience
2015-01-01 Petrioli, R.; Roviello, G.; Laera, L.; Luzzi, L.; Paladini, P.; Ghiribelli, C.; Voltolini, L.; Martellucci, I.; Bianco, V.; Francini, E.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients
2010-01-01 Correale, P.; Remondo, C.; Carbone, S. F.; Ricci, V.; Migali, C.; Martellucci, I.; Licchetta, A.; Addeo, R.; Volterrani, L.; Gotti, G.; Rotundo, M. S.; Tassone, P.; Sperlongano, P.; Abbruzzese, A.; Caraglia, M.; Tagliaferri, P.; Francini, G.
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
2018-01-01 Petrioli, Roberto; Chirra, Martina; Messuti, Luciana; Fiaschi, Anna Ida; Savelli, Vinno; Martellucci, Ignazio; Francini, Edoardo
First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: A real-life setting study with gender prospective
2021-01-01 Spini, A.; Gini, R.; Rosellini, P.; Singier, A.; Bellan, C.; Pascucci, A.; Leoncini, L.; Mathieu, C.; Martellucci, I.; Furiesi, F.; Giorgi, S.; Donnini, S.; Roberto, G.; Ziche, M.; Salvo, F.
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
2020-01-01 Petrioli, R.; Torre, P.; Pesola, G.; Paganini, G.; Paolelli, L.; Miano, S. T.; Martellucci, I.; Francini, G.; Francini, E.
Head and Neck Carcinoma and biomarker profiling: searching tumor identity card.
2023-01-01 Martellucci, Ignazio
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)
2008-01-01 Correale, P.; Tagliaferri, P.; Fioravanti, A.; DEL VECCHIO, M. T.; Remondo, C.; Montagnani, F.; Rotundo, M. S.; Ginanneschi, C.; Martellucci, I.; Francini, E.; Cusi, M. G.; Tassone, P.; Francini, G.
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab
2009-01-01 Remondo, C.; Migali, C.; Martellucci, I.; Carbone, F.; Ricci, V.; Addeo, R.; Del Prete, S.; Fulfaro, F.; Francini, G.; Correale, P.
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study
2009-01-01 Correale, P.; Remondo, C.; Migali, C.; Licchetta, A.; Martellucci, I.; Carbone, S. F.; Ricci, V.; Addeo, R.; Del Prete, S.; Francini, Guido
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients
2011-01-01 Correale, P.; Botta, C.; Basile, A.; Pagliuchi, M.; Licchetta, A.; Martellucci, I.; Bestoso, E.; Apollinari, S.; Addeo, R.; Misso, G.; Romano, O.; Abbruzzese, A.; Lamberti, M.; Luzzi, L.; Gotti, G.; Rotundo, M. S.; Caraglia, M.; Tagliaferri, P.
Porcelain gallbladder and its relationship to cancer
2021-01-01 Calomino, N.; Scheiterle, M. L. P. F.; Fusario, D.; La Francesca, N.; Martellucci, I.; Marrelli, D.
Sjögren's syndrome and aromatase inhibitors treatment: is there a link?
2013-01-01 Guidelli, G. M.; Martellucci, I.; Galeazzi, M.; Francini, G.; Fioravanti, A.
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
2013-01-01 Botta, C.; Barbieri, V.; Ciliberto, D.; Rossi, A.; Rocco, D.; Addeo, R.; Staropoli, N.; Pastina, Pierpaolo; Marvaso, G.; Martellucci, Ignazio; Guglielmo, A.; Pirtoli, Luigi; Sperlongano, P.; Gridelli, C.; Caraglia, M.; Tassone, P.; Tagliaferri, P.; Correale, P.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin
2010-01-01 Petrioli, R.; Bargagli, G.; Lazzi, Stefano; Pascucci, A.; Francini, E.; Bellan, Cristiana; Conca, R.; Martellucci, I.; Fiaschi, A. I.; Lorenzi, B.; Francini, Guido; Multidisciplinary Oncology Group in Gastrointestinal, Tumors; Civitelli, Serenella
Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients
2020-01-01 Palmieri, M.; Baldassarri, M.; Fava, F.; Fabbiani, A.; Gelli, E.; Tita, R.; Torre, P.; Petrioli, R.; Hadijstilianou, T.; Galimberti, D.; Cinotti, E.; Bengala, C.; Mandala, M.; Piu, P.; Miano, S. T.; Martellucci, I.; Vannini, A.; Pinto, A. M.; Mencarelli, M. A.; Marsili, S.; Renieri, A.; Frullanti, E.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients | 1-gen-2006 | Correale, P.; Cerretani, D.; Remondo, C.; Martellucci, I.; Marsili, S.; La Placa, M.; Sciandivasci, A.; Paolelli, L.; Pascucci, A.; Rossi, M.; Di Bisceglie, M.; Giorgi, G.; Gotti, G.; Francini, G. | - | |
| Bevacizumab and weekly Doxetacel in patients with metastatic castrate-resistant prostate cancer previously exposed to Docetaxel | 1-gen-2011 | Francini, F.; Pascucci, A.; Francini, E.; Bargagli, G.; Conca, R.; Licchetta, A.; Roviello, G.; Martellucci, I.; Chiriacò, G.; Miano, S:t.; Marzocca, G.; Manganelli, A.; Ponchietti, R.; Savelli, V.; Petrioli, R. | - | |
| Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: A single-institution experience | 1-gen-2015 | Petrioli, R.; Roviello, G.; Laera, L.; Luzzi, L.; Paladini, P.; Ghiribelli, C.; Voltolini, L.; Martellucci, I.; Bianco, V.; Francini, E. | - | |
| Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients | 1-gen-2010 | Correale, P.; Remondo, C.; Carbone, S. F.; Ricci, V.; Migali, C.; Martellucci, I.; Licchetta, A.; Addeo, R.; Volterrani, L.; Gotti, G.; Rotundo, M. S.; Tassone, P.; Sperlongano, P.; Abbruzzese, A.; Caraglia, M.; Tagliaferri, P.; Francini, G. | - | |
| Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy | 1-gen-2018 | Petrioli, Roberto; Chirra, Martina; Messuti, Luciana; Fiaschi, Anna Ida; Savelli, Vinno; Martellucci, Ignazio; Francini, Edoardo | - | |
| First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: A real-life setting study with gender prospective | 1-gen-2021 | Spini, A.; Gini, R.; Rosellini, P.; Singier, A.; Bellan, C.; Pascucci, A.; Leoncini, L.; Mathieu, C.; Martellucci, I.; Furiesi, F.; Giorgi, S.; Donnini, S.; Roberto, G.; Ziche, M.; Salvo, F. | - | |
| Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer | 1-gen-2020 | Petrioli, R.; Torre, P.; Pesola, G.; Paganini, G.; Paolelli, L.; Miano, S. T.; Martellucci, I.; Francini, G.; Francini, E. | - | |
| Head and Neck Carcinoma and biomarker profiling: searching tumor identity card. | 1-gen-2023 | Martellucci, Ignazio | - | |
| Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) | 1-gen-2008 | Correale, P.; Tagliaferri, P.; Fioravanti, A.; DEL VECCHIO, M. T.; Remondo, C.; Montagnani, F.; Rotundo, M. S.; Ginanneschi, C.; Martellucci, I.; Francini, E.; Cusi, M. G.; Tassone, P.; Francini, G. | - | |
| Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab | 1-gen-2009 | Remondo, C.; Migali, C.; Martellucci, I.; Carbone, F.; Ricci, V.; Addeo, R.; Del Prete, S.; Fulfaro, F.; Francini, G.; Correale, P. | - | |
| Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study | 1-gen-2009 | Correale, P.; Remondo, C.; Migali, C.; Licchetta, A.; Martellucci, I.; Carbone, S. F.; Ricci, V.; Addeo, R.; Del Prete, S.; Francini, Guido | - | |
| Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients | 1-gen-2011 | Correale, P.; Botta, C.; Basile, A.; Pagliuchi, M.; Licchetta, A.; Martellucci, I.; Bestoso, E.; Apollinari, S.; Addeo, R.; Misso, G.; Romano, O.; Abbruzzese, A.; Lamberti, M.; Luzzi, L.; Gotti, G.; Rotundo, M. S.; Caraglia, M.; Tagliaferri, P. | - | |
| Porcelain gallbladder and its relationship to cancer | 1-gen-2021 | Calomino, N.; Scheiterle, M. L. P. F.; Fusario, D.; La Francesca, N.; Martellucci, I.; Marrelli, D. | - | |
| Sjögren's syndrome and aromatase inhibitors treatment: is there a link? | 1-gen-2013 | Guidelli, G. M.; Martellucci, I.; Galeazzi, M.; Francini, G.; Fioravanti, A. | - | |
| Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. | 1-gen-2013 | Botta, C.; Barbieri, V.; Ciliberto, D.; Rossi, A.; Rocco, D.; Addeo, R.; Staropoli, N.; Pastina, Pierpaolo; Marvaso, G.; Martellucci, Ignazio; Guglielmo, A.; Pirtoli, Luigi; Sperlongano, P.; Gridelli, C.; Caraglia, M.; Tassone, P.; Tagliaferri, P.; Correale, P. | - | |
| Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin | 1-gen-2010 | Petrioli, R.; Bargagli, G.; Lazzi, Stefano; Pascucci, A.; Francini, E.; Bellan, Cristiana; Conca, R.; Martellucci, I.; Fiaschi, A. I.; Lorenzi, B.; Francini, Guido; Multidisciplinary Oncology Group in Gastrointestinal, Tumors; Civitelli, Serenella | - | |
| Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients | 1-gen-2020 | Palmieri, M.; Baldassarri, M.; Fava, F.; Fabbiani, A.; Gelli, E.; Tita, R.; Torre, P.; Petrioli, R.; Hadijstilianou, T.; Galimberti, D.; Cinotti, E.; Bengala, C.; Mandala, M.; Piu, P.; Miano, S. T.; Martellucci, I.; Vannini, A.; Pinto, A. M.; Mencarelli, M. A.; Marsili, S.; Renieri, A.; Frullanti, E. | - |